{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/palliative-care-nausea-vomiting/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"b433057a-92f0-5457-837c-f3f7235e44e6","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 2a896a28-2355-4bf6-87de-e877a55e5dd9 --><h2>Changes</h2><!-- end field 2a896a28-2355-4bf6-87de-e877a55e5dd9 -->","summary":null,"htmlStringContent":"<!-- begin item 88c6843b-0021-4b4c-8c23-eb92152a1f5e --><!-- begin field d0a18af7-ef64-4b2b-b768-6515c50b5398 --><p><strong>October 2020 </strong>— minor update. Reference to levomepromazine 6 mg being unlicensed has been removed from this topic as a licensed product is now available.</p><p><strong>July 2015 to October 2016</strong> — reviewed. Literature searches were conducted in September 2016 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. There have been structural changes to the topic and changes to the recommendations have been updated in line with NICE guidance <em>Care of dying adults in the last days of life </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">NICE, 2015</a>].</p><!-- end field d0a18af7-ef64-4b2b-b768-6515c50b5398 --><!-- end item 88c6843b-0021-4b4c-8c23-eb92152a1f5e -->","topic":{"id":"8a2e6dd8-7d6f-5fcf-a744-1b12e2a14232","topicId":"329a162f-132a-4d7e-afd5-7ff2f86369d2","topicName":"Palliative care - nausea and vomiting","slug":"palliative-care-nausea-vomiting","lastRevised":"Last revised in October 2020","chapters":[{"id":"4cf6ed2e-fa29-54e9-8d93-4bd52407c5c4","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"2e3a3e75-af78-5547-a042-7aa68a341672","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"27d24f4a-dbc8-560f-b100-ca5287022d66","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"b433057a-92f0-5457-837c-f3f7235e44e6","slug":"changes","fullItemName":"Changes"},{"id":"540b41fe-3e71-5c29-9379-7493711a8a59","slug":"update","fullItemName":"Update"}]},{"id":"ed201382-7c29-58e9-ba5d-f5c415eb3bf3","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"7043600f-13dd-5980-b06d-73dab2266896","slug":"goals","fullItemName":"Goals"},{"id":"63b87fa3-3c3d-527b-9ac2-e856dd0c559e","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6e3ee330-3c0d-5735-b8d5-76b606865d07","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"d1227949-2a90-5b29-abef-3895e05333c3","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e2e036e5-217a-593d-947f-a8376f0f5e98","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"3885ba7b-9d6f-5262-a541-463284363660","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b65bec71-2fa0-54e0-be57-13a917c2a697","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a9561403-d5a9-5c9c-b6e6-c24410e9d9d3","slug":"definition","fullItemName":"Definition"},{"id":"d92b4aee-031c-58a4-b4b9-5d13767e0261","slug":"prevalence","fullItemName":"Prevalence"},{"id":"b1327253-7b93-5a44-b2f7-5e002ae90e8f","slug":"causes","fullItemName":"Causes"},{"id":"e321f36e-5ec2-5074-b128-109efef69a65","slug":"complications","fullItemName":"Complications"}]},{"id":"a4a81f08-7894-5ba4-a4e5-c5505f3e5250","fullItemName":"Management","slug":"management","subChapters":[{"id":"8691c12d-3ed6-5e16-bef3-667d198f6707","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"e2566bf0-9d82-5bc7-9b5f-835384f56bc2","slug":"known-cause","fullItemName":"Scenario: Known cause"},{"id":"c8237819-4755-5cd8-ad7c-12735068c87a","slug":"unknown-cause","fullItemName":"Scenario: Unknown cause"},{"id":"145fe4aa-682c-5299-9906-a7bca2e98a9b","slug":"end-of-life","fullItemName":"Scenario: End of life"}]},{"id":"4d9745dc-8b36-500d-8e94-0e51611a4373","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"f61e929d-def9-58db-877e-a030bc91d3de","slug":"prescribing-an-anti-emetic","fullItemName":"Prescribing an anti-emetic"},{"id":"d39c4487-f9dc-5d1d-be98-95561ca991bd","slug":"prescribing-a-prokinetic","fullItemName":"Prescribing a prokinetic"},{"id":"23e74db2-9671-539b-8bcf-b5c4bdff23f9","slug":"prescribing-haloperidol","fullItemName":"Prescribing haloperidol"},{"id":"00a2a0a3-8bc1-5d27-a03f-6cd4624d1c38","slug":"prescribing-levomepromazine","fullItemName":"Prescribing levomepromazine"},{"id":"d0437d3a-566f-5df2-9800-1961ed4664e8","slug":"prescribing-cyclizine","fullItemName":"Prescribing cyclizine"},{"id":"e6d5c2a8-e2b8-55c5-afd4-46f2edcd4a30","slug":"prescribing-dexamethasone","fullItemName":"Prescribing dexamethasone"},{"id":"3042d096-a74b-5c66-8d18-8c233091e783","slug":"prescribing-hyoscine-butylbromide","fullItemName":"Prescribing hyoscine butylbromide"}]},{"id":"ba414d8a-38a1-5962-84ab-6051ffe6dfe9","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"26e42d0a-9ee9-50c5-9f2b-818da289f6e9","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"c0795c41-1865-5ab1-b820-e41b8b5d9aab","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"3076afc1-a703-524e-9ec9-995b34c4d386","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"08b8fc57-db22-518d-a528-777cb4e8d7dc","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"81928ac1-4f26-5da9-b11f-85d1cee4fbdd","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"5aee10d5-2771-547a-a52a-1fb430319da3","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"3cfa53b2-3d63-508d-80ea-c2a6293844fc","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"27d24f4a-dbc8-560f-b100-ca5287022d66","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"57fbe9e9-c45a-5afd-b614-348de5745987","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 90117937-7e15-4b89-83ca-7238a52dfaec --><h3>Previous changes</h3><!-- end field 90117937-7e15-4b89-83ca-7238a52dfaec -->","summary":null,"htmlStringContent":"<!-- begin item 69b28828-6844-4a1b-b1e9-f11d2a6309fc --><!-- begin field bf26276a-e546-4ed8-81e6-892b206c603d --><p><strong>July 2015 </strong>— topic title changed to reflect broader topic coverage than specifically cancer care.</p><p><strong>July 2014 </strong>— minor update. Update to the text to state that although the European Medicines Agency (EMA) has issued advice restricting the use of metoclopramide and domperidone, following clarification from the EMA this advice does not apply to unlicensed uses of metoclopramide (for example palliative care).</p><p><strong>June 2013 </strong>— minor update. The 2013 QOF options for local implementation have been added to this topic.</p><p><strong>September 2012 </strong>— reviewed. A literature search was conducted in August 2012 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of this topic. No major changes to recommendations have been made.</p><p><strong>March 2012 </strong>— minor update. The 2012/2013 QOF indicators have been added to this topic. Issued in April 2012.</p><p><strong>January 2012 </strong>— minor update. McNeil Products Ltd, in collaboration with the Medicines and Healthcare products Regulatory Agency (MHRA), has published new safety data regarding the association of domperidone with an increased risk of serious ventricular arrhythmias or sudden cardiac death. This topic has been updated to reflect their advice on dosing, adverse effects, and drug interactions. Issued in February 2012.</p><p><strong>May 2011 </strong>— minor update. The 2011/2012 QOF indicators have been added to this topic. Issued in June 2011.</p><p><strong>February 2011 </strong>— topic structure revised to ensure consistency across CKS topics — no changes to clinical recommendations have been made.</p><p><strong>July to October 2007 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail and recommendations are more clearly justified and transparently linked to the supporting evidence. A section has been added covering the management of nausea and vomiting at the end of life. The emphasis of this CKS topic is on the treatment of nausea and vomiting in a palliative care situation; malignant bowel obstruction has been included, but in less detail than previously.</p><p><strong>January 2006 </strong>— minor update. Prescriptions for diamorphine updated to reflect the change in handwriting requirements for controlled drug prescriptions. Issued in February 2006.</p><p><strong>October 2005 </strong>— minor technical update. Issued in November 2005.</p><p><strong>March 2004 </strong>— written in March 2004. Validated in June 2004 and issued in July 2004.</p><!-- end field bf26276a-e546-4ed8-81e6-892b206c603d --><!-- end item 69b28828-6844-4a1b-b1e9-f11d2a6309fc -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}